Advertisement

PharmacoEconomics & Outcomes News

, Volume 842, Issue 1, pp 28–28 | Cite as

Secukinumab cost effective for active psoriatic arthritis

Clinical study
  • 4 Downloads

Reference

  1. Gandjour A, et al. Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany. Applied Health Economics and Health Policy : 7 Nov 2019. Available from: URL: http://doi.org/10.1007/s40258-019-00523-1

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations